Monopar Q3 Loss Widens to $6.2M as R&D Spend Jumps; $129.4M Cash Lasts to March 2028
MNPR sits 40% above its 52-week low of $50.07.
Summary
Monopar's Q3 2026 net loss widened to $6.2M, or $0.72 per share, from $3.4M, or $0.48 per share, a year earlier, driven by R&D expense rising to $4.4M from $2.6M on contractor and personnel costs. The company held $129.4M in cash, cash equivalents and investments at September 30, 2026, and says that funds operations through at least March 31, 2028. For a clinical-stage company with a roughly $481M market cap, that runway removes near-term financing risk and keeps the focus on the ALXN1840 NDA submission. The wider loss is a cost story, not a cash scare — the balance sheet covers the spend. The next hard checkpoint is completing the NDA submission and the FDA's filing and review decisions.
At the time of this announcement, MNPR was trading at $70.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $481.5M. The 52-week trading range was $50.07 to $124.82. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.